Alzheimer's Disease (AD) Clinical Trials


A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

Condition:   Dementia
Interventions:   Drug: Xanamem™;   Drug: Placebo (for Xanamem™)
Sponsors:   Actinogen Medical;   ICON Clinical Research
Recruiting - verified July 2017

Learn More

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

Conditions:   Dementia With Lewy Bodies;   REM Sleep Behavior Disorder;   Parkinson's Disease Dementia
Interventions:   Drug: Nelotanserin;   Drug: Placebo
Sponsor:   Axovant Sciences Ltd.
Recruiting - verified June 2017

Learn More

CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Condition:   Alzheimer's Disease
Interventions:   Drug: Crenezumab;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified June 2017

Learn More

Neurotrack Test Validation Protocol

Condition:   Mild Cognitive Impairment
Intervention:  
Sponsors:   New York University School of Medicine;   NeuroTrack Technologies, Inc.
Recruiting - verified July 2017

Learn More

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Condition:   Alzheimer's Disease
Interventions:   Drug: SUVN-502;   Drug: Placebo
Sponsor:   Suven Life Sciences Limited
Recruiting - verified July 2017

Learn More

An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

Condition:   Asymptomatic Amyloid-positive
Interventions:   Drug: JNJ-54861911, 5 mg;   Drug: JNJ-54861911, 25 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified June 2017

Learn More

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Condition:   Alzheimer's Disease
Interventions:   Biological: CAD106 Immunotherapy;   Other: Placebo to CAD106;   Drug: CNP520;   Other: Placebo to CNP520
Sponsors:   Novartis Pharmaceuticals;   Banner Alzheimer's Institute;   National Institute on Aging (NIA);   Alzheimer's Association;   Amgen
Recruiting - verified July 2017

Learn More

Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function

Conditions:   Alzheimer's Disease;   Obesity;   Diabetes Mellitus
Interventions:   Dietary Supplement: Boost A;   Behavioral: Healthy Living Diet
Sponsor:   National Institute on Aging (NIA)
Recruiting - verified February 8, 2017

Learn More

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Conditions:   Schizophrenia;   Alzheimer Disease
Interventions:   Drug: BI 409306 matching placebo;   Drug: BI 409306 matching placebo;   Drug: BI 409306;   Drug: BI 409306
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2017

Learn More

Translation of COPE for Publicly-Funded Home Care Clients and Their Families

Conditions:   Dementia;   Alzheimer's Disease
Intervention:   Behavioral: Care of Persons with Dementia in their Environments
Sponsor:   UConn Health
Recruiting - verified July 2017

Learn More

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Condition:   Alzheimer Disease
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: BI 409306;   Drug: Donepezil
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2017

Learn More

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Condition:   Alzheimer´s Disease
Interventions:   Drug: Lanabecestat;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   AstraZeneca
Recruiting - verified July 2017

Learn More

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

Condition:   Alzheimer Disease
Interventions:   Drug: BI 409306;   Drug: Placebo;   Drug: BI 409306;   Drug: Placebo;   Drug: Placebo;   Drug: BI 409306;   Drug: BI 409306;   Drug: Placebo;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2017

Learn More

Genetic Characterization of Movement Disorders and Dementias

Conditions:   Ataxia;   Dystonia;   Parkinson's Disease;   Amyotrophic Lateral Sclerosis;   Corticobasal Degeneration;   Multiple System Atrophy;   Alzheimer's Disease;   Lewy Body Dementia;   Parkinson Disease-Dementia;   Dentatorubral-pallidoluysian Atrophy;   Creutzfeldt-Jakob Disease and Fatal Familial Insomnia;   Fragile X-associated Tremor/Ataxia Syndrome;   Krabbe's Disease;   Niemann-Pick Disease, Type C;   Neuronal Ceroid Lipofuscinosis
Intervention:  
Sponsor:   National Institute on Aging (NIA)
Recruiting - verified April 11, 2017

Learn More

Bisnorcymserine in Healthy Adult Volunteers

Condition:   Alzheimer's Disease
Intervention:   Drug: BNC
Sponsor:   National Institute on Aging (NIA)
Recruiting - verified March 16, 2017

Learn More

31-45 of 48
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.